Summit Therapeutics reported a GAAP net loss of $208.4 million for the third quarter of 2026, as the company prepares for a critical regulatory decision regarding its lead candidate, ivonescimab. The company maintained a strong liquidity position that was significantly bolstered post-quarter by a transformative strategic investment from AstraZeneca, providing substantial runway for its expanding global clinical development program.
Key Highlights
- Cash and short-term investments totaled $629.8 million as of September 30, 2026, which excludes the $2.0 billion strategic equity investment from AstraZeneca completed on October 5, 2026.
- The FDA has set a PDUFA goal action date of November 14, 2026, for the Biologics License Application of ivonescimab in combination with chemotherapy for certain lung cancer patients.
- Research and development expenses increased to $169.1 million from $131.1 million year-over-year, driven by the expansion of multiregional clinical studies and development costs for ivonescimab.